Cardiovascular Deal Benchmarks
Heart failure, hypertension, ATTR cardiomyopathy, and PAH deal benchmarks. Benchmarks derived from 68 verified transactions.
68
Total Deals
$384M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
29
license
20
acquisition
12
collaboration
2
option
3
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Tenaya Therapeutics Inc. → Alnylam Pharmaceuticals Inc. | collaboration | $10M | $1.1B | Mar 2026 |
35Pharma → GSK HS235 | acquisition | $950M | $950M | Feb 2026 |
Unnatural Products → Novartis | collaboration | $100M | $1.8B | Feb 2026 |
CSL Ltd. → Eli Lilly clazakizumab | license | $100M | — | Feb 2026 |
ProFound Therapeutics → Novartis novel therapies | collaboration | $25M | $775M | Jul 2025 |
Argo Biopharmaceutical → Novartis cardiovascular risk reduction | license | $160M | $5.2B | Jul 2025 |
Tourmaline Bio → Novartis Pacibekitug (CV) | acquisition | $770M | $1.5B | May 2025 |
Jiangsu Hengrui → Merck HRS-5346 | license | $200M | $2.0B | Mar 2025 |
Anthos Therapeutics → Novartis Abelacimab | acquisition | $925M | $3.1B | Feb 2025 |
Verve Therapeutics → Eli Lilly VERVE-201 (Lp(a) gene editing) | acquisition | $598M | $2.5B | Jan 2025 |
Benchmark Your Cardiovascular Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 68 verified cardiovascular transactions.
Run Cardiovascular Benchmark